ScripScrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their respon
ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
In VivoThe contraceptive market is one famously defined by its lack of innovation. Despite pioneering attempts by researchers to bring new contraceptive options to market – particularly efforts to develop a
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ovid Taps Gensaic’s Approach To Neurolo